|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 904.70 INR | -1.76% |
|
+1.86% | -1.06% |
| Feb. 11 | India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment | RE |
| Feb. 11 | Zydus Lifesciences enters settlement agreement with Astellas over Myrbetriq | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYDUS LIFESCIENCES LIMITED | Generic Pharmaceuticals | -1.76% | +1.86% | -1.06% | -4.05% | +93.29% | 10.05B |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- ZYDUSLIFE Stock
- Charts Zydus Lifesciences Limited
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
